Most of the existing cathepsin-activatable fluorescent imaging agents are directed against cathepsin B, L, and/or S. Therefore, this immunohistochemical study investigated the expression of these cathepsins in TMAs of a large cohort of breast cancer patients. The gene discussed is CTSB; the disease is breast carcinoma.